Case File
efta-02509430DOJ Data Set 11OtherEFTA02509430
Date
Unknown
Source
DOJ Data Set 11
Reference
efta-02509430
Pages
3
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From:
jeffrey E. <[email protected]>
Sent:
Thursday, February 19, 2015 5:35 PM
To:
Hosain Rahman
Subject:
Re: Mort: Exchange Offer
my guys are supposed to have a call with your poeple today=C2 thanks
On Thu, Feb 19, 2015 at 11:49 AM, Hosain Rahman <=
<mailto
wrote:
> >
Hi - see below the offer is to convert your common into higher price= preferred at a 3.5X ratio. Gives you a really
nice guaranteed returned on=the old shares.
We are closing this out soon, so =anted to make sure you had the opportunity to participate. Let me know if =ou
have any questions.
Begin forwarded mes=age:
From: Hosain Rahma= <hrahman@jawb=ne.com <mailto
Date: February 16, 2015 at 2:00:38 PM MST
T=: Jeffrey Epstein <[email protected] <mailto:[email protected]»
Subject: Fwd: Mort: =xchange Offer
FYI
Begin forward=d message:
From: Anna P=dkovyrova
<mailto
Date: February 16, 2015 at 1:50:37 P= MST
To: "Hosain Rahman " <
<mailto
<mailto
Cc: Will Hawthorne <
<mailto
Subj=ct: Mort: Exchange Offer
> >
> >
> >
», Andrew Lindsa=
EFTA_R1_01640735
EFTA02509430
<=span>
Andrew,=C2
aspan>
Wanted =o clearly lay out the exchange offer as it pertains to Mort.
<=span>
Exch=nge offer
For eac= new share of Series 6 preferred purchased, Mort gets to take a share of c=mmon stock and
convert it to 3.5 shares of Series 6 preferred.
As you =now Series 6 has a lx liquidation preference and is senior to all other ro=nds, so this offer
allows the common to move up in the stack to be the mos= senior equity and gives them a liquidation price of $39.44 a
share ($11.26 x 3.5).
It is a= amazing offer for shareholders that own common.
aspan>
See =elow — if they invest $14mm now they end up with $64mm (5.7mm shar=s x $11.26) of Series 6
Liquidation Preference:
Please visit http://www.codeadvisors.com/disclaimer.html for important d=sclaimer information
regarding this communication.
please =ote
The information contained in this communication is confiden=ial, may be attorney-client privileged, may constitute
inside informati=n, and is intended only for the use of the addressee. It is the propert= of JEE Unauthorized use,
disclosure or copying of this communica=ion or any part thereof is strictly prohibited and may be unlawful. If =ou have
received this communication in error, please notify us immediat=ly by return e-mail or by e-mail to
2
EFTA_R1_01640736
EFTA02509431
[email protected] <mailto:jeevacation@gmail=com> , and destroy this comm=nication and all copies thereof,
including all attachments. copyright -=11 rights reserved
3
EFTA_R1_01640737
EFTA02509432
Technical Artifacts (6)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Domain
ne.comEmail
[email protected]Phone
2509430Phone
2509431Phone
2509432URL
http://www.codeadvisors.com/disclaimer.htmlRelated Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.